Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S17-S20 , April 2003

Targeting Outflow Facility in Glaucoma Management

  • Richard F Brubaker, MD

      Affiliations

    • Corresponding Author InformationReprint address: Richard F. Brubaker, MD, Dept. of Ophthalmology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

References 

  1. Asrani S, Zeimer R, Wilensky J, et al.  Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142
  2. Becker B, Shaffer RN: Diagnosis and therapy of the glaucomas. St Louis, Missouri, Mosby, 1965 (ed 2), pp 54–6
  3. Brown B, Burton P, Mann S, Parisi A. Fluctuations in intra- ocular pressure with sleep (II. Time course of IOP decrease after waking from sleep). Ophthalmic Physiol Opt. 1988;8:249–252
  4. Brubaker R. Measurement of uveoscleral outflow in humans. J Glaucoma. 2001;10(Suppl 1):S45–S48
  5. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S347–S351
  6. Brubaker RF, Schoff EO, Nau CB, et al.  Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol. 2001;131:19–24
  7. Ellingsen BA, Grant WM. The relationship of pressure and aqueous outflow in enucleated human eyes. Invest Ophthalmol. 1971;10:430–437
  8. Erickson-Lamy KA, Nathanson JA. Epinephrine increases facility of outflow and cyclic AMP content in the human eye in vitro. Invest Ophthalmol Vis Sci. 1992;33:2672–2678
  9. Gharagozloo NZ, Relf SJ, Brubaker RF. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988;95:1217–1220
  10. Grant WM. Clinical measurements of aqueous outflow. Arch Ophthalmol. 1951;46:113–131
  11. Heijl A, Leske MC, Bengtsson B, et al.  Reduction of intraocular pressure and glaucoma progression (results from the Early Manifest Glaucoma Trial). Arch Ophthalmol. 2002;120:1268–1279
  12. Johnson DH, Tschumper RC. Human trabecular meshwork organ culture. A new method. Invest Ophthalmol Vis Sci. 1987;28:945–953
  13. Kaufman PL, Bárány EH. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest Ophthalmol. 1976;15:793–807
  14. Saito M, Takano R, Shirato S. Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma. Am J Ophthalmol. 2001;132:485–489
  15. Sakurai M, Araie M, Oshika T, et al.  Effects of topical application of UF-021, a novel prostaglandin derivative, on aqueous humor dynamics in normal human eyes. Jpn J Ophthalmol. 1991;35:156–165
  16. Topper JE, Brubaker RF. Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep. Invest Ophthalmol Vis Sci. 1985;26:1315–1319
  17. Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128:8–14
  18. Toris CB, Camras CB, Yablonski ME. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 1993;100:1297–1304
  19. Toris CB, Zhan GL, Zhao J, et al.  Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol. 2001;131:722–728
  20. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978;27:135–142
  21. Ziai N, Dolan JW, Kacere RD, Brubaker RF. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 1993;11:1351–1358

PII: S0039-6257(03)00003-1

doi: 10.1016/S0039-6257(03)00003-1

Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S17-S20 , April 2003

Article Tools

* Image Usage & Resolution